You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
翰森製藥(03692.HK)向Regeneron授出產品許可 獲首付款8,000萬美元
阿思達克 06-02 22:09
翰森製藥(03692.HK)公布,全資附屬上海翰森生物醫藥及江蘇豪森藥業與Regeneron Pharmaceuticals, Inc.(REGN.US)訂立許可協議。據此,公司向Regeneron授予開發、生產及商業化HS-20094的全球獨佔許可(不含內地、香港及澳門),公司將獲得8,000萬美元首付款,並收取最高19.3億美元里程碑付款,以及未來潛在產品銷售的雙位數百分比特許權使用費。 HS-20094是一款在研GLP-1/GIP雙受體激動劑,已成功完成多項II期試驗,具有積極的療效和安全性數據,目前正在中國進行III期臨床試驗。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account